Biosense Webster receives FDA approval for Thermocool Smarttouch SF Ablation Catheter for the persistent atrial fibrillation

Bidding open for ZRG Medical Auctions - Bid Now - Closes Dec 11th

Biosense Webster receives FDA approval for Thermocool Smarttouch SF Ablation Catheter for the persistent atrial fibrillation

Press releases may be edited for formatting or style | October 07, 2020 Cardiology
IRVINE, Calif., Oct. 6, 2020 /PRNewswire/ -- Johnson & Johnson Medical Devices Companies** today announced the United States Food and Drug Administration (FDA) approval of Biosense Webster, Inc.'s THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the treatment of persistent atrial fibrillation (persistent AF).† The approval is based on results of a prospective, multi-center study (PRECEPT) which met primary safety and effectiveness endpoints and demonstrated 80 percent of persistent AF patients experienced clinical success at 15 months after ablation therapy using the THERMOCOOL SMARTTOUCH SF Catheter with the CARTO VISITAG™ Module.‡1,2 In addition, patients experienced clinically meaningful improvement in quality of life and the study showed significant reduction in healthcare resource utilization post-ablation.1,2

Atrial fibrillation (AF) is a significant public health issue affecting the health of millions of people and placing a critical burden on healthcare systems. Persistent AF is defined as continuous AF that lasts for more than seven days and up to one year. The management of persistent AF aims to prevent AF recurrence and associated disabilities while reducing side effects from treatment.

"Every patient and every arrhythmia are unique," said Dr. Francis Marchlinski***, Director of Electrophysiology, University of Pennsylvania Health System. "This approval and the PRECEPT data provide evidence to support a tailored approach using the CARTO® 3 System and THERMOCOOL SMARTTOUCH SF Catheter to treat persistent AF patients, who are more at risk for stroke and other complications from their AF."

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

The PRECEPT study is the first prospective, multi-center investigational device exemption study designed to evaluate the safety and effectiveness of radiofrequency (RF) catheter ablation in patients with persistent AF, and was conducted using the THERMOCOOL SMARTTOUCH SF Catheter. Results of the PRECEPT study demonstrated 80 percent of persistent AF patients experienced clinical success at 15 months after ablation therapy and 86 percent experienced freedom from repeat procedures at 15 months.3 The CARTO 3 System and THERMOCOOL SMARTTOUCH SF Catheter allow for a patient-tailored ablation approach, resulting in high long-term effectiveness in a more advanced persistent AF patient group (continuous AF > 7 days < 1 year).*2

Radiofrequency ablation with the THERMOCOOL SMARTTOUCH SF Catheter led to a clinically meaningful improvement in Quality of Life (QOL), as well as a reduction in antiarrhythmic drug (AAD) use, cardioversion and hospitalization in persistent AF patients.§3

You Must Be Logged In To Post A Comment